Notice of Intent - Nucleic acid�based reagents for in vivo transient protein expression
Health and Human Services, Department of · OFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)
This notice is not accepting responses (deadline was Feb 14, 2026, 1:00 PM EST).
Page kept for research and related open opportunities below. For current work in this category, use the related notices or browse hubs.
- Response deadline
- Feb 14, 2026, 1:00 PM EST
- Posted
- Jan 30, 2026
- Solicitation
- NIH-26-006363-IntentNotice
- Set-aside
- No Set aside used
- Place of performance
- Philadelphia, PA, USA
- Contracting office
- PROGRAM SUPPORT CENTER ACQ MGMT SVC · ROCKVILLE · MD
- Source
- SAM.gov · updated Jul 5, 2026
Description
This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only. Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update. ------------------------------------------------------------------------------------------------------------------------ The intent is to award a contract on a solesource basis instead of competititon for Nucleic acid�based reagents for in vivo transient protein expression forthe National Cancer Institute and Center for Cancer Research. The supplies required are nucleic acid-based reagents. The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models. Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.
What similar awards have paid
Real federal awards already on the books in a similar lane — so you can size the opportunity, not guess. This is public history, not a bid price, cost estimate, or prediction that you will win.
Typical award size
$81,118
Middle of the pack for similar past awards
Most similar awards fall between $27,273 and $203,180
Who has won work like this
Public awardees in this lane — useful for competitor scan or teaming ideas, not a ranked list of “best” firms.
- 1ACCESS BIO, INC.1 award$88.70M
- 2CEPHEID110 awards$57.71M
- 3ATLANTIC TRADING LLC1 award$26.51M
- 4BIOMERIEUX INC106 awards$22.98M
- 5ROCHE DIAGNOSTICS CORPORATION94 awards$19.40M
- 6ABBOTT MOLECULAR INC.16 awards$11.19M
- 7BIOFIRE DIAGNOSTICS LLC19 awards$10.86M
- 8ORASURE TECHNOLOGIES INC2 awards$6.60M
Drawn from official USAspending contract records in our index. Always confirm requirements on the SAM.gov notice before you bid.
Intelligence only — not legal advice or a guarantee of award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Notice ID e3675be32c5f47f3801816ac68017a33.